Top Markets
#1 0G 0G +42.31%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.73%
#3 Useless Coin Useless Coin +35.33%
#4 SAFEcoin SAFEcoin +30.67%
#5 StonkBroker StonkBroker +27.91%
#6 Arbitrum Arbitrum +26.80%
#7 Notcoin Notcoin +19.30%
#8 Full Moon Full Moon +18.20%
#9 Zora Zora +17.22%
#10 rsERG rsERG +15.54%
Coin of the day
0G 0G
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
Kedudukan dalam Saham #13821
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Harga Saham
$12.63
Modal Pasaran
$458.19M
Perubahan (1 hari)
-3.26%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Evommune, Inc. (EVMN)

Kategori

Healthcare
Pendapatan untuk Evommune, Inc. (EVMN)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Evommune, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Evommune, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH